Incidence, predictors and clinical outcome of pancreatic fistula in patients receiving splenectomy for advanced or recurrent ovarian cancer: a large multicentric experience.
Cytoreduction
Ovarian cancer
Pancreatectomy
Pancreatic fistula
Splenectomy
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
05
02
2020
accepted:
04
07
2020
pubmed:
11
7
2020
medline:
28
10
2020
entrez:
11
7
2020
Statut:
ppublish
Résumé
To evaluate the incidence, predictors and clinical outcome of pancreatic fistulas in patients receiving splenectomy during cytoreductive surgery for advanced or recurrent ovarian cancer. Data of women who underwent splenectomy during cytoreduction for advanced or recurrent ovarian cancer from December 2012 to May 2018 were retrospectively retrieved from the oncological databases of five institutions. Surgical, post-operative and follow-up data were analysed. Overall, 260 patients were included in the study. Pancreatic resection was performed in 45 (17.6%) women, 23 of whom received capsule resection alone, while 22 required tail resection. Hyperthermic intraperitoneal chemotherapy (HIPEC) was administered in 28 (10.8%) patients. In the overall population, a pancreatic fistula was detected in 32 (12.3%) patients, and pancreatic resection (p-value = 0.033) and HIPEC administration (p-value = 0.039) were associated with fistula development. In multivariate analysis, HIPEC (OR = 2.573; p-value = 0.058) was confirmed as a risk factor for fistula development in women receiving splenectomy alone, while concomitant cholecystectomy (OR = 2.680; p-value = 0.012) was identified as the only independent predictor of the occurrence of pancreatic fistulas in those receiving additional distal pancreatectomy. Although the median length of hospital stay was higher in women with pancreatic leakage (p-value = 0.008), the median time from surgery to adjuvant treatment was not significantly increased. HIPEC was identified as a risk factor for pancreatic fistulas in patients who underwent splenectomy alone, while concomitant cholecystectomy was the only independent predictor of fistula in those receiving additional pancreatectomy. The development of pancreatic leakage was not associated with increased post-operative mortality or delay in the initiation of chemotherapy.
Identifiants
pubmed: 32648028
doi: 10.1007/s00404-020-05684-2
pii: 10.1007/s00404-020-05684-2
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
707-714Références
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA cancer J Clin 61:69–90
doi: 10.3322/caac.20107
Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS (2008) The effect of maximal surgical cytoreduction on sensitivity to platimun-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108:276–281
doi: 10.1016/j.ygyno.2007.10.022
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259
doi: 10.1200/JCO.2002.20.5.1248
Eisenhauer EL, Abu-Rustum NR (2006) Sonoda Y et Al: The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103:1083–1090
doi: 10.1016/j.ygyno.2006.06.028
Hoffman MS, Tebes SJ, Sayer RA, Lockart J (2007) Extended cytoreduction of intraabdominal metastatic ovarian cancer in the left upper quadrant utilizing en bloc resection. AM J Obstet Gynecol 197:209–204
doi: 10.1016/j.ajog.2007.04.049
Kehoe SM, Eisenhauer EL, Chi DS (2008) Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy and distal pancreatectomy. Gynecol Oncol 111:S51–S55
doi: 10.1016/j.ygyno.2008.07.053
Zapardiel I, Peiretti M, Zanagnolo V et al (2012) Splenectomy as part of primary cytoreductive surgery for advanced ovarian cancer, a retrospective cohort study. Int J Gynecol Cancer 22:968–973
doi: 10.1097/IGC.0b013e3182571479
Bacalbasa N, Balescu I, Dima S, Brasoveanu V, Popescu I (2015) Splenectomy as part of cytoreductive surgery in recurrent epithelial ovarian cancer. Anticancer Res 35(9):5097–5101
pubmed: 26254413
Sun H, Bi X, Cao D et al (2018) Splenectomy during cytoreductive surgery in epithelial ovarian cancer. Cancer Manag Res 12(10):3473–3482
doi: 10.2147/CMAR.S172687
Kehoe SM, Eisenhauer EL, Abu-Rustum NR et al (2009) Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer. Gynecol Oncol 112:496–500
doi: 10.1016/j.ygyno.2008.10.011
Xiang L, Tu Y, He T et al (2016) Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer. J Gynecol Oncol 27(6):e62
doi: 10.3802/jgo.2016.27.e62
Benedetti Panici P, Di Donato V (2015) Fischetti M et Al: Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery. Gynecol Oncol 137:406–411
doi: 10.1016/j.ygyno.2015.03.043
Young J, Badgery-Parker T, Dobbins T et al (2015) Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. J Pain Symptom Manage 49(2):258–264
doi: 10.1016/j.jpainsymman.2014.06.006
Zeppernick F, Meinhold-Heerlein I (2014) The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet 290(5):839–842
doi: 10.1007/s00404-014-3364-8
Petrillo M, Vizzielli G, Fanfani F et al (2015) Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecol Oncol 139(1):5–9
doi: 10.1016/j.ygyno.2015.07.095
Jimenez RE, Mavanur A, Macaulay WP (2007) Staple line reinforcement reduces postoperative pancreatic stump leak after distal pancreatectomy. J Gastrointest Surg 11:345–349
doi: 10.1007/s11605-006-0034-6
Pratt WB, Maithel SK, Vanounou T et al (2007) Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg 245:443–451
doi: 10.1097/01.sla.0000251708.70219.d2
Bassi C, Marchegiani G, Dervenis C et al (2017) International Study Group on Pancreatic Surgery (ISGPS) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 161(3):584–591
doi: 10.1016/j.surg.2016.11.014
Crippa S, Salvia R, Falconi M, Butturini G, Landoni L, Bassi C (2007) Anastomotic leakage in pancreatic surgery. HPB (Oxford) 9(1):8–15
doi: 10.1080/13651820600641357
Van Driel WJ, Koole SN, Sonke GS (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(14):1363–1364
pubmed: 29617590
Spiliotis J, Halkia E, Lianos E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575
doi: 10.1245/s10434-014-4157-9
Chassagne D, Sismondi P, Horiot JC et al (1993) A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol 26:195–202
doi: 10.1016/0167-8140(93)90260-F
Eisenkop SM, Spirtos NM (2001) Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol 82:435–441
doi: 10.1006/gyno.2001.6313
Mikkelsen MS, Christiansen T, Petersen LK, Blaakaer J, Iversen LH (2019) Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer. J Surg Oncol 120(3):550–557
doi: 10.1002/jso.25603
McDonnell CO, Bailey I, Stumpf T et al (2002) The effect of cholecystectomy on plasma cholecystokinin. Am J Gastroenterol 97(9):2189–2192
doi: 10.1111/j.1572-0241.2002.05971.x
Schernhammer ES, Michaud DS, Leitzmann MF et al (2002) Gallstones, cholecystectomy, and the risk for developing pancreatic cancer. Br J Cancer 86(7):1081–1084
doi: 10.1038/sj.bjc.6600193
Kazanjian KK, Hines OJ, Eibl G, Reber HA (2005) Management of pancreatic fistulas after pancreaticoduodenectomy. Arch Surg 140:849–855
doi: 10.1001/archsurg.140.9.849
Conlon KC, Labow D, Leung D et al (2001) Prospective randomized clinical trial of the value of intraperitoneal drainage after pancreatic resection. Ann Surg 234:487–493
doi: 10.1097/00000658-200110000-00008
Connor S, Raraty MG, Howes N et al (2005) Surgery in the treatment of acute pancreatitis-minimal access pancreatic necrosectomy. Scand J surg 94(2):135–142
doi: 10.1177/145749690509400210
Rotman SR, Kahaleh M (2012) Pancreatic fluid collection drainage by endoscopic ultrasound: new perspectives. Endosc Ultrasound 1(2):61–68
doi: 10.7178/eus.02.002
Zeng Q, Zhang Q, Han S et al (2008) Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas 36:18–25
doi: 10.1097/mpa.0b013e3181343f5d
Gurusamy KS, Koti R, Fusai G, Davidson BR (2013) Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev 30(4):008370
Allen PJ, Gönen M, Brennan MF et al (2014) Pasireotide for postoperative pancreatic fistula. N Engl J Med 370(21):2014–2022
doi: 10.1056/NEJMoa1313688
Elliott IA, Dann AM, Ghukasyan R et al (2018) Pasireotide does not prevent postoperative pancreatic fistula: a prospective study. HPB (Oxford) 20(5):418–422
doi: 10.1016/j.hpb.2017.10.018
Zizzo M, Ugoletti L, Manenti A et al (2019) Pasireotide for the prevention of postoperative pancreatic fistula: an open debate. HPB (Oxford) 21(7):930–931
doi: 10.1016/j.hpb.2019.01.010